Is there a role for adjuvant treatment after hepatic resection for hepatocellular carcinoma?

Oncology

Volumn 78, Issue 3-4, 2010, Pages 161-171

  Tan, Ann ^a   Aucejo, Federico ^b   Kim, Richard ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Adjuvant therapy; Curative resection; Hepatocellular carcinoma

Indexed keywords

ALPHA INTERFERON; ALPHA1B INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; CARMOFUR; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IODINATED POPPYSEED OIL; IODINATED POPPYSEED OIL I 131; IODINE 131; MITOMYCIN; PI 88; POLYPRENOIC ACID; SORAFENIB; UFT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOPTIVE IMMUNOTHERAPY; ALOPECIA; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CHEMOEMBOLIZATION; DERMATITIS; DIARRHEA; DRUG MECHANISM; FEVER; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER RESECTION; LIVER TRANSPLANTATION; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT; WOUND HEALING IMPAIRMENT;

CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRA-ARTERIAL; LIVER; LIVER NEOPLASMS; MALE; PROGNOSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953125020     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000315577     Document Type: Review

References (67)

1. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94: 153-156.
2. Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC: Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009; 1:CD001199.
3. Cherqui D: Role of adjuvant treatment in liver transplantation for advanced hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 1998; 5: 35-40.
4. Altekruse SF, McGlynn KA, Reichman ME: Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-1491.
5. El-Serag HB, Marrero JA, Rudolph L, Reddy KR: Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 1752-1763.
6. Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J: Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg 1995; 221: 291-298.
7. Llovet JM, Bruix J, Gores GJ: Surgical resection versus transplantation for early hepatocellular carcinoma: clues for the best strategy. Hepatology 2000; 31: 1019-1021.
8. Mazzaferro V, Regalia E, Doci R, et al: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
9. Shetty K, Timmins K, Brensinger C, et al: Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004; 10: 911-918.
10. Bismuth H, Houssin D, Ornowski J, Meriggi F: Liver resections in cirrhotic patients: a Western experience. World J Surg 1986; 10: 311-317.
11. Fan ST, Lo CM, Liu CL, et al: Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg 1999; 229: 322-330.
12. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A: Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993; 218: 145-151. (Pubitemid 23229140)
13. Farmer DG, Rosove MH, Shaked A, Busuttil RW: Current treatment modalities for hepatocellular carcinoma. Ann Surg 1994; 219: 236-247.
14. Chen MF, Hwang TL, Jeng LB, Jan YY, Wang CS, Chou FF: Hepatic resection in 120 patients with hepatocellular carcinoma. Arch Surg 1989; 124: 1025-1028.
15. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J: Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000; 89: 500-507.
16. Mazzaferro V, Romito R, Schiavo M, et al: Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44: 1543-1554.
17. el-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Yu L, Nagasue N: Proposal of invasiveness score to predict recurrence and survival after curative hepatic resection for hepatocellular carcinoma. Surgery 1997; 122: 571-577.
18. Kubo S, Hirohashi K, Tanaka H, et al: Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma. Cancer 2000; 88: 1016-1024. (Pubitemid 30127660)
19. Wu CC, Ho WL, Chen JT, Tang JS, Yeh DC, Peng FK: Hepatitis viral status in patients undergoing liver resection for hepatocellular carcinoma. Br J Surg 1999; 86: 1391-1396.
20. Hanazaki K, Wakabayashi M, Sodeyama H, Kajikawa S, Amano J: Hepatic function immediately after hepatectomy as a significant risk factor for early recurrence in hepatocellular carcinoma. Hepatogastroenterology 1999; 46: 3201-3207.
21. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al: Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 2000; 31: 302-308.
22. Yamamoto M, Arii S, Sugahara K, Tobe T: Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br J Surg 1996; 83: 336-340.
23. Ono T, Nagasue N, Kohno H, et al: Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study. Semin Oncol 1997; 24(2 Suppl 6):S6-18-S6-25.
24. Hasegawa K, Takayama T, Ijichi M, et al: Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology 2006; 44: 891-895.
25. Davis AJ, Tannock JF: Repopulation of tumour cells between cycles of chemotherapy: a neglected factor. Lancet Oncol 2000; 1: 86-93.
26. Ono T, Yamanoi A, Nazmy El Assal O, Kohno H, Nagasue N: Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer 2001; 91: 2378-2385.
27. Lau WY, Lai EC, Leung TW, Yu SC: Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg 2008; 247: 43-48.
28. Lau WY, Leung TW, Ho SK, et al: Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999; 353: 797-801.
29. Partensky C, Sassolas G, Henry L, Paliard P, Maddern GJ: Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study. Arch Surg 2000; 135: 1298-1300.
30. Boucher E, Corbinais S, Rolland Y, et al: Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma. Hepatology 2003; 38: 1237-1241. (Pubitemid 37314832)
31. Tabone M, Vigano L, Ferrero A, Pellerito R, Carbonatto P, Capussotti L: Prevention of intrahepatic recurrence by adjuvant (131)iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis. Eur J Surg Oncol 2007; 33: 61-66.
32. Ren ZG, Lin ZY, Xia JL, et al: Postoperative adjuvant arterial chemoembolization improves survival of hepatocellular carcinoma patients with risk factors for residual tumor: a retrospective control study. World J Gastroenterol 2004; 10: 2791-2794.
33. Fan J, Zhou J, Wu ZQ, et al: Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2005; 11: 1215-1219. (Pubitemid 40353011)
34. Zhong C, Guo RP, Li JQ, et al: A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol 2009; 135: 1437-1445.
35. Lai EC, Lo CM, Fan ST, Liu CL, Wong J: Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg 1998; 133: 183-188.
36. Castells A, Bruix J, Ayuso C, et al: Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. J Hepatol 1995; 22: 410-415.
37. Chung JW, Park JH, Han JK, et al: Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996; 198: 33-40.
38. Georgiades CS, Hong K, D'Angelo M, Geschwind JF: Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005; 16: 1653-1659.
39. Baron S, Tyring SK, Fleischmann WR Jr, et al: The interferons. Mechanisms of action and clinical applications. JAMA 1991; 266: 1375-1383.
40. Singh RK, Gutman M, Bucana CD, Sanchez R, Llansa N, Fidler IJ: Interferons alpha and beta down-regulate the expression of basic fibroblast growth factor in human carcinomas. Proc Natl Acad Sci USA 1995; 92: 4562-4566.
41. Ikeda K, Saitoh S, Suzuki Y, et al: Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer 1998; 82: 827-835.
42. Yoshida H, Shiratori Y, Moriyama M, et al: Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131: 174-181.
43. Lai CL, Wu PC, Lok AS, et al: Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial. Br J Cancer 1989; 60: 928-933.
44. Lo CM, Liu CL, Chan SC, et al: a randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007; 245: 831-842.
45. Sun HC, Tang ZY, Wang L, et al: Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006; 132: 458-465.
46. Ikeda K, Arase Y, Saitoh S, et al: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor -a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32: 228-232.
47. Kubo S, Nishiguchi S, Hirohashi K, et al: Effects of long-term postoperative interferonalpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001; 134: 963-967.
48. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H: Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002; 89: 418-422. (Pubitemid 34595504)
49. Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Mullhaupt B, Clavien PA: Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009; 96: 975-981.
50. Rosenberg SA, Yannelli JR, Yang JC, et al: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994; 86: 1159-1166.
51. Takayama T, Sekine T, Makuuchi M, et al: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356: 802-807.
52. Moriwaki H, Muto Y, Ninomiya M, Kawai K, Suzuki Y, Seto T: Inhibitory effects of synthetic acidic retinoid and polyprenoic acid on the development of hepatoma in rats induced by 3′ -methyl-N, N-dimethyl-4-aminoazobenzene. Gastroenterol Jpn 1988; 23: 546-552.
53. Muto Y, Moriwaki H, Ninomiya M, et al: Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996; 334: 1561-1567. (Pubitemid 26177483)
54. Muto Y, Moriwaki H, Saito A: Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999; 340: 1046-1047.
55. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, Kojiro M: Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998; 28: 68-77.
56. Thomas MB, Abbruzzese JL: Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005; 23: 8093-8108.
57. Ferro V, Dredge K, Liu L, et al: PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost 2007; 33: 557-568.
58. Liu CJ, Lee PH, Lin DY, et al: Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 2009; 50: 850-853.
59. Chang YS, Adnane J, Trail PA, et al: Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007; 59: 561-574.
60. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
61. Del Pozo AC, Lopez P: Management of hepatocellular carcinoma. Clin Liver Dis 2007; 11: 305-321.
62. Llovet JM, Schwartz M, Mazzaferro V: Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis 2005; 25: 181-200.
63. Chan ES, Chow PK, Tai B, Machin D, Soo K: Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma. Cochrane Database Syst Rev 2000; 2:CD001199.
64. Schwartz JD, Schwartz M, Mandeli J, Sung M: Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002; 3: 593-603.
65. Nagasue N, Kohno H, Chang YC, et al: Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg 1993; 217: 375-384. (Pubitemid 23115341)
66. Izumi R, Shimizu K, Iyobe T, et al: Postoperative adjuvant hepatic arterial infusion of lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 1994; 20: 295-301.
67. Kohno H, Nagasue N, Hayashi T, et al: Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC). Hepatogastroenterology 1996; 43: 1405-1409.